Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension

Zuzana Honetschlägerová, Zuzana Husková, Zdeňka Vaňourková, Alexandra Sporková, Herbert J. Kramer, Sung Hee Hwang, Hsing-Ju Tsai, Bruce D. Hammock, John D. Imig, Luděk Červenka, Libor Kopkan

. 2011 ; 589 (Pt 1) : 207-219.

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12027281

Grant support
NS9699 MZ0 CEP Register
NS10499 MZ0 CEP Register

In the present study, we examined the effects of soluble epoxide hydrolase (sEH) inhibition on the development of angiotensin II-dependent hypertension and on renal function in transgenic rats with inducible expression of the mouse renin gene (strain name Cyp1a1-Ren-2). Hypertension was induced in these rats by indole-3-carbinol (I3C; 0.3% in the diet) for 12 days. The sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) was given in two doses (13 or 26 mg l-1) in drinking water. Blood pressure (BP), body weight (BW) and renal excretory parameters were monitored in conscious animals during the experiment. Renal haemodynamics was assessed at the end of treatment in anaesthetized rats. I3C administration resulted in severe hypertension with a rise in systolic BP from 118 ± 2 to 202 ± 3 mmHg, a loss of BW from 266 ± 5 to 228 ± 4 g and a rise in proteinuria from 14 ± 2 to 34 ± 3 mg day-1. Both doses of c-AUCB significantly attenuated the development of hypertension (systolic BP of 181 ± 4 and 176 ± 4 mmHg, respectively), the loss in BW (256 ± 4 and 259 ± 3 g, respectively) and the degree of proteinuria (27 ± 2 and 25 ± 3 mg day-1, respectively) to a similar extent. Moreover, c-AUCB prevented the reduction in renal plasma flow (5.4 ± 0.4 vs. 4.6 ± 0.3 ml min-1 g-1) and significantly increased sodium excretion (0.84 ± 0.16 vs. 0.38 ± 0.08 μmol min-1 g-1) during I3C administration. These data suggest that the oral administration of c-AUCB displays antihypertensive effects in Ren-2 transgenic rats with inducible malignant hypertension via an improvement of renal function.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027281
003      
CZ-PrNML
005      
20160315163233.0
007      
ta
008      
120816s2011 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1113/jphysiol.2010.199505 $2 doi
035    __
$a (PubMed)21078594
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Honetschlägerová, Zuzana $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
245    10
$a Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension / $c Zuzana Honetschlägerová, Zuzana Husková, Zdeňka Vaňourková, Alexandra Sporková, Herbert J. Kramer, Sung Hee Hwang, Hsing-Ju Tsai, Bruce D. Hammock, John D. Imig, Luděk Červenka, Libor Kopkan
520    9_
$a In the present study, we examined the effects of soluble epoxide hydrolase (sEH) inhibition on the development of angiotensin II-dependent hypertension and on renal function in transgenic rats with inducible expression of the mouse renin gene (strain name Cyp1a1-Ren-2). Hypertension was induced in these rats by indole-3-carbinol (I3C; 0.3% in the diet) for 12 days. The sEH inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) was given in two doses (13 or 26 mg l-1) in drinking water. Blood pressure (BP), body weight (BW) and renal excretory parameters were monitored in conscious animals during the experiment. Renal haemodynamics was assessed at the end of treatment in anaesthetized rats. I3C administration resulted in severe hypertension with a rise in systolic BP from 118 ± 2 to 202 ± 3 mmHg, a loss of BW from 266 ± 5 to 228 ± 4 g and a rise in proteinuria from 14 ± 2 to 34 ± 3 mg day-1. Both doses of c-AUCB significantly attenuated the development of hypertension (systolic BP of 181 ± 4 and 176 ± 4 mmHg, respectively), the loss in BW (256 ± 4 and 259 ± 3 g, respectively) and the degree of proteinuria (27 ± 2 and 25 ± 3 mg day-1, respectively) to a similar extent. Moreover, c-AUCB prevented the reduction in renal plasma flow (5.4 ± 0.4 vs. 4.6 ± 0.3 ml min-1 g-1) and significantly increased sodium excretion (0.84 ± 0.16 vs. 0.38 ± 0.08 μmol min-1 g-1) during I3C administration. These data suggest that the oral administration of c-AUCB displays antihypertensive effects in Ren-2 transgenic rats with inducible malignant hypertension via an improvement of renal function.
650    _2
$a aplikace orální $7 D000284
650    _2
$a angiotensin II $7 D000804
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x aplikace a dávkování $x farmakologie $7 D000959
650    _2
$a kyseliny arachidonové $x metabolismus $7 D001095
650    _2
$a benzoáty $x aplikace a dávkování $x farmakologie $7 D001565
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a cytochrom P-450 CYP1A1 $x genetika $7 D019363
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a inhibitory enzymů $x aplikace a dávkování $x farmakologie $7 D004791
650    _2
$a epoxid hydrolasy $x antagonisté a inhibitory $x metabolismus $7 D004851
650    _2
$a hodnoty glomerulární filtrace $x účinky léků $7 D005919
650    _2
$a kyseliny hydroxyeikosatetraenové $x metabolismus $7 D006893
650    _2
$a hypertenze $x chemicky indukované $x enzymologie $x genetika $x patofyziologie $x prevence a kontrola $7 D006973
650    _2
$a ledviny $x krevní zásobení $x účinky léků $x enzymologie $x patofyziologie $7 D007668
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a proteinurie $x metabolismus $x patofyziologie $x prevence a kontrola $7 D011507
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a renální průtok plazmy $x účinky léků $7 D017595
650    _2
$a renin $x genetika $x metabolismus $7 D012083
650    _2
$a sodík $x moč $7 D012964
650    _2
$a časové faktory $7 D013997
650    _2
$a močovina $x aplikace a dávkování $x analogy a deriváty $x farmakologie $7 D014508
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Husková, Zuzana, $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $d 1978- $7 xx0074206
700    1_
$a Vaňourková, Zdeňka, $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $d 1973- $7 xx0074217
700    1_
$a Sporková, Alexandra $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic
700    1_
$a Kramer, Herbert J $u Section of Nephrology, Medical Policlinic, Department of Medicine, University of Bonn, Bonn, Germany
700    1_
$a Hwang, Sung Hee $u Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
700    1_
$a Tsai, Hsing-Ju $u Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
700    1_
$a Hammock, Bruce D. $u Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA
700    1_
$a Imig, John D. $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA
700    1_
$a Červenka, Luděk, $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Physiology, 2nd Medical Faculty, Charles University, Prague, Czech Republic $d 1967- $7 xx0037105
700    1_
$a Kopkan, Libor $u Department of Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Center for Cardiovascular Research, Prague, Czech Republic $7 xx0107287
773    0_
$w MED00002907 $t The Journal of physiology $x 1469-7793 $g Roč. 589, č. Pt 1 (2011), s. 207-219
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21078594 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160315162951 $b ABA008
999    __
$a ok $b bmc $g 949323 $s 784627
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 589 $c Pt 1 $d 207-219 $i 1469-7793 $m Journal of physiology (London. Print) $n J Physiol (Lond) $x MED00002907
GRA    __
$a NS9699 $p MZ0
GRA    __
$a NS10499 $p MZ0
LZP    __
$b NLK112 $a Pubmed-20120816/11/02

Find record

Citation metrics

Archiving options